NCT02316964 - Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2015

Primary Completion Date

December 6, 2017

Study Completion Date

December 20, 2019

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Interventions

DRUG

decitabine

20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes

BIOLOGICAL

natural killer cell therapy

Undergo infusion of allogeneic NK cells on day 0

BIOLOGICAL

aldesleukin

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

All Listed Sponsors

lead

Sumithira Vasu

OTHER